Patents by Inventor Timothy F. Briggs

Timothy F. Briggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
    Patent number: 11813272
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 14, 2023
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME
    Publication number: 20230293458
    Abstract: Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.
    Type: Application
    Filed: May 25, 2023
    Publication date: September 21, 2023
    Inventors: John Patrick CASEY, David Arthur BERRY, Alfredo CASTRO, Steven John TAYLOR, Ferdinand Edward MASSARI, John Robert PROUDFOOT, Elijah Lane BOGART, Timothy F. BRIGGS
  • ASPARAGINE DERIVATIVES AND METHODS OF USING SAME
    Publication number: 20230234917
    Abstract: The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 27, 2023
    Inventors: Spencer Cory PECK, Jenny LIU, Timothy F. BRIGGS, John Robert PROUDFOOT, William MCELROY, Robert Walter MYERS, Steven John TAYLOR
  • BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME
    Publication number: 20230181493
    Abstract: The present disclosure relates to the treatment of Parkinson's disease. The present disclosure provides, in some embodiments, methods of treating Parkinson's disease in a patient in need thereof. In some embodiments, the methods disclosed herein comprise administering a levodopa therapy based on a patient's biomarker profile. In some embodiments, the levodopa therapy comprises or lacks a tyrosine decarboxylase inhibitor. Therapeutic uses and compositions are also disclosed.
    Type: Application
    Filed: April 9, 2021
    Publication date: June 15, 2023
    Inventors: Devin Forest Reed DOUD, Afrand KAMALI, Victoria CATANZANO, Yohannes TEFFERA, Spencer Cory PECK, William McELROY, Timothy F. BRIGGS, Steven John TAYLOR
  • ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20220296555
    Abstract: Disclosed herein are acylated active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: John Patrick CASEY, JR., David Arthur BERRY, Timothy F. BRIGGS, Leonard BUCKBINDER, Mi-Jeong KIM, Anna LIANG, Anushya PANDIAN
  • ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20220296563
    Abstract: Disclosed herein are acylated active agents (e.g., acylated hydroxybenzoic acid), compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: John Patrick CASEY, JR., David Arthur BERRY, Timothy F. BRIGGS, Leonard BUCKBINDER, Mi-Jeong KIM, Anna LIANG
  • ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20220110960
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Steven John TAYLOR, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Koji YASUDA, Leonard BUCKBINDER, Bernard LANTER, Spencer Cory PECK, Cheri SNEDEKER, Angela SHE, Jessica ALEXANDER, Anna LIANG, Jenny LIU, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR., Amir H. MOAREFI
  • ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20210283157
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Application
    Filed: May 13, 2021
    Publication date: September 16, 2021
    Inventors: Steven John TAYLOR, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Koji YASUDA, Leonard BUCKBINDER, Bernard LANTER, Spencer Cory PECK, Cheri SNEDEKER, Angela SHE, Jessica ALEXANDER, Anna LIANG, Jenny LIU, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR., Amir H. MOAREFI
  • Acylated active agents and methods of their use for the treatment of autoimmune disorders
    Patent number: 11058698
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 13, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
  • ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20210177877
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Application
    Filed: November 17, 2020
    Publication date: June 17, 2021
    Inventors: Steven John TAYLOR, John Robert PROUDFOOT, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Afrand KAMALI SARVESTANI, Leonard BUCKBINDER, Bernard LANTER, Ferdinand Edward MASSARI, Koji YASUDA, Spencer Cory PECK, Cheri SNEDEKER, Diana LE, Jessica ALEXANDER, Anna LIANG, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
  • ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER
    Publication number: 20210085640
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating a cancer marker or for treating cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: March 25, 2021
    Inventors: Steven John TAYLOR, Leonard BUCKBINDER, John Robert PROUDFOOT, Mi-Jeong KIM, Timothy F. BRIGGS, Ferdinand Edward MASSARI, Spencer Cory PECK, Koji YASUDA, Amir MOAREFI, David Arthur BERRY, John Patrick CASEY, JR.
  • Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
    Patent number: 10953027
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 23, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20200197428
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 25, 2020
    Inventors: Steven John TAYLOR, John Robert PROUDFOOT, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Afrand KAMALI SARVESTANI, Leonard BUCKBINDER, Bernard LANTER, Ferdinand Edward MASSARI, Koji YASUDA, Spencer Cory PECK, Cheri SNEDEKER, Diana LE, Jessica ALEXANDER, Anna LIANG, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
  • ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20200188418
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 18, 2020
    Inventors: Steven John TAYLOR, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Koji YASUDA, Leonard BUCKBINDER, Bernard LANTER, Spencer Cory PECK, Cheri SNEDEKER, Angela SHE, Jessica ALEXANDER, Anna LIANG, Jenny LIU, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
  • MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME
    Publication number: 20200101030
    Abstract: Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.
    Type: Application
    Filed: December 3, 2019
    Publication date: April 2, 2020
    Inventors: John Patrick CASEY, JR., David Arthur BERRY, Alfredo CASTRO, Steven John TAYLOR, Ferdinand Edward MASSARI, John Robert PROUDFOOT, Elijah Lane BOGART, Timothy F. BRIGGS
  • Macrocyclic compounds for modulating IL-17
    Patent number: 9284283
    Abstract: The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17-associated disorders.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: March 15, 2016
    Assignee: Ensemble Therapeutics Corporation
    Inventors: Michael Taylor, Nicholas K. Terrett, William H. Connors, Cheri Snedeker, Kelley C. Shortsleeves, Benjamin A. Seigal, Stephen P. Hale, Timothy F. Briggs, Frank G. Favaloro, Jr., Tyler J. Cipriani, Dingxue Yan, Sethu L. Alexander, Atli Thorarensen, Li Xing
  • MACROCYCLIC COMPOUNDS FOR MODULATING IL-17
    Publication number: 20150005319
    Abstract: The invention relates generally to macrocyclic compounds of formula I and their therapeutic use. More particularly, the invention relates to macrocyclic compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17-associated disorders.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 1, 2015
    Inventors: Michael Taylor, Nicholas K. Terrett, William H. Connors, Cheri Snedeker, Kelley C. Shortsleeves, Benjamin A. Seigal, Stephen P. Hale, Timothy F. Briggs, Frank G. Favaloro, Jr., Tyler J. Cipriani, Dingxue Yan, Sethu L. Alexander, Atli Thorarensen, Li Xing
  • Macrocyclic compounds for inhibition of tumor necrosis factor alpha
    Patent number: 8338565
    Abstract: Disclosed herein are macrocyclic compounds and methods for their synthesis and use. In particular, macrocyclic compounds are disclosed that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: December 25, 2012
    Assignee: Ensemble Therapeutics Corporation
    Inventors: Jinbo Lee, Julian F. Bond, Nicholas Terrett, Frank G. Favaloro, Jr., Daniel Wang, Timothy F. Briggs, Benjamin Adam Seigal, Wei-Chuan Sun, Stephen P. Hale
  • MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA
    Publication number: 20100152099
    Abstract: The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.
    Type: Application
    Filed: August 20, 2009
    Publication date: June 17, 2010
    Inventors: Jinbo Lee, Julian F. Bond, Nicholas Terrett, Frank G. Favaloro, JR., Daniel Wang, Timothy F. Briggs, Benjamin A. Seigal, Wei-Chuan Sun, Stephen P. Hale